Severe aplastic anaemia is a life-threatening bone marrow failure condition requiring combination immunosuppressive therapy plus a thrombopoietin receptor agonist. Dallas's UT Southwestern and Baylor University Medical Center manage these complex cases, and Rompag 50mg provides a high-dose option at significantly reduced cost.
Rompag is used at doses up to 150mg daily in aplastic anaemia patients undergoing combination immunosuppressive therapy — clinical trials showed adding Eltrombopag produced complete haematologic responses in over 90% of previously untreated patients.
Dallas hospital pharmacies can access Rompag at significantly lower cost than brand Revolade.
|
FAQ: Why is Eltrombopag combined with other
immunosuppressive drugs rather than used alone? Severe aplastic anaemia
involves the immune system attacking bone marrow stem cells, so treatment
needs to address both the destruction (via immunosuppression) and stimulate
new blood cell production (via Eltrombopag). Used alone, Eltrombopag wouldn't
address the underlying autoimmune process. The combination achieves
substantially higher response rates. |
